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Background: B7-H3 and matrix metalloproteinases 2 (MMP-2) are reported highly expressed in malignant tumor,
we investigate the relationship between B7-H3 expression and MMP-2 on malignant behavior and prognosis
predictable value in pancreatic cancer.
Methods: We tested the expressions of B7-H3 and MMP-2 protein in 45 pancreatic surgical resected cancer
samples; meanwhile, the clinicopathological data of enrolled patients were obtained for correlation analysis to
obtain their relationship with pancreatic cancer progress.
Results: The expression of B7-H3 was up-regulated with infiltrating depth, lymph node metastasis and TNM stage
(P < 0.01). Positive expression rate of MMP-2 in pancreatic cancer tissues was 44.35%, whereas negative in normal
pancreatic tissues. Multivariate analysis of Logistic regression showed B7-H3 and MMP-2 expressions were
hazardous makers correlated with infiltrating depth (P < 0.05).
Conclusion: Our study showed combined detections of B7-H3 and MMP2 protein expression could identify
patients at high risk in disease recurrence and prognosis more efficiently.
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Pancreatic cancer is one of the most aggressive and intract-
able cancers worldwide and a leading cause of cancer-
related deaths [1]. The crude mortality rate of pancreatic
cancer in China was 4.34% of the total cancer deaths [2].
It is calculated that, overall, pancreatic cancer is the fourth
most common cause of cancer death, the overall survival
of pancreatic cancer is <5% at 5 years. More than half of
the patients have advanced disease with distant metastases
at diagnosis [3]. The majority of pancreatic cancer is dis-
covered at late stage and is therefore incurable, over the
last decade several groups have embarked on screening
individuals with recognized genetic syndromes or a
significant family history for pancreatic cancer [4]. Al-
though there is substantial diversity among the screened* Correspondence: jianjunqian99@163.com
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reproduction in any medium, provided the orpopulations, these studies provide important information
about the yield of these strategies [5].
B7-H3 (CD276) is a member of the B7 family and is
expressed by lymphoid cells, such as dendritic cells,
monocytes/macrophages and activated Tcells; non-lymphoid
tissue cells express B7-H3 too, such as epithelial cells, anter-
ior pituitary progenitor cells, muscle cells and fibroblast-like
synoviocytes [6,7], B7-H3 was reported expressed in non-
small cell lung cancer, prostate cancer, neuroblastoma and
renal cell carcinoma [8-10]. The expression of B7-H3 seems
to correlate with clinicopathological features or poor prog-
nosis [7,10], but there is one report demonstrating better
survival in patients with gastric carcinoma B7-H3+ tumours
[11]. These contradictory evidences suggest that single
tumor marker is not sensitive or specific enough for
tumor detection. Joint use of information from multiple
markers may be more effective to reveal association be-
tween prognosis and data than single marker analysis.
The knock-down of B7-H3 lead to matrix metallopro-
teinase (MMP)-2, another tumor prognostic marker cellThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical data of 45 pancreatic cancer patients
Cases
number
Stage Pathology type Therapy
DA AC Others RS PS RS + C PS + C
9 I 8 1 7 1 1 /
11 II 10 / 1 6 / 5 /
12 III 10 1 1 3 / 7 2
13 IV 9 2 2 / 1 / 12
Abbreviation used: DA Ductal Adenocarcinoma, AC Adenosquamous Carcinoma,
RS Radical Surgery, PS Palliative Surgery, C Chemotherapy.
Chemotherapy including: Gemzar monotherapy, Gemzar + Oxaliplatin
and Gemzar + Capecitabine.
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teinases) are thought to play a major role on degrade all
kinds of extracellular matrix proteins, and are regarded
as a marker of malignant tumor invasion and metastasis
[13-15]. Overexpression of various MMPs, particularly
MMP-2, is correlated with poor prognosis in many types
cancer including adrenocortical cancer, breast cancer,
and thyroid malignancies [16,17].
There have been no studies conducted to elucidate
the associations between MMP-2 and B7-H3 expression
in pancreatic cancer prognosis. In present study, we
analyzed the clinical significance of MMP-2 and B7-H3




Pancreatic cancer tissue samples were obtained from pa-
tients who underwent pancreatic cancer surgery at our
hospital from March in 2007. The study was approved
by the ethics committee of Subei People’s Hospital, and
all patients gave informed consent before surgery. Benign
pancreatic tissues (confirmed by pathology) from operation
were chosen as control.
TNM classification of these patients were recorded
according to the proposed by the International Union
against Cancer in 2003 [18]. Tissue samples were trimmed
to proper volume and fixed in 10% formalin solution or
stored at −80°C immediately. Histological examination was
performed to verify the collected tissues in all samples.
Quantitative RT-PCR for B7-H3
A total of 50 mg of −70°C frozen tissues were grind in
liquid nitrogen bath. Extracts homogenized in 1 mL of
buffer. After 15 min incubation on ice, the lysates were
centrifuged at 12,000 rpm for 5 min at 4°C, and then
the supernatants were removed. Precipitate resuspended
in 100 μL B buffer, and shaken for 30 min at 4°C followed
by centrifuge at 12,000 rpm for 15 min. 2 μL supernatants
were mixed with 20 μL PCR solution buffer, and then
reacted 30 min for extension at 30°C, 95°C for 10 min;
followed 45 cycles of 95°C for 10 s, 63°C (55°C for
GAPDH) for 20 s, and 72°C for 20s; a final extension at
55°C for 25 min, and a 4°C incubation.
Primer and probe sequences of B7-H3 and GAPDH
were designed to assess the mRNA expression of each
marker for RT-PCR. The forward primers, probe sequence
and reverse primers for B7-H3 and GAPDH were: B7-H3
(forward), 5′ -GACAGCAAAGAAGATGATGGA- 3′;
(probe), 5′-FAM-CCTCCCTACAGCTCCTACCCTCTGG-
TAMRA-1-3′; (reverse), 5′-ACCTGTCAGAGCAGGATGC-
3′; GAPDH (forward), 5′-GGGTGTGAACCATGAGA
AGT- 3′; (probe), 5′-FAM-CAGCAATGCCTCCTGCA
CCACCAA-TAMRA-1-3′; (reverse), 5′-GACTGTGGTCATGAGTCCT-3′, respectively. The integrity of the RNA
was confirmed in a denaturing agarose gel using GAPDH
as control.
All total RNA samples were reverse transcribed using
the Advantage RT-for-PCR kit (Clontech Laboratories,
Inc., Palo Alto, CA, USA). Samples were analyzed by
quantitative RT-PCR (qRT-PCR) using the LightCycler
System (Roche Diagnostics, Mannheim, Germany). B7-H3
mRNA copy numbers were normalized by GAPDH mRNA
copy numbers (relative B7-H3 mRNA copies: absolute
B7-H3 mRNA copies ⁄ absolute GAPDH mRNA copies).
Immuno-histochemistry analyzing expression of B7-H3
and MMP-2 in tissues
The expression of B7-H3 proteins were evaluated in 45
tissue blocks of pancreatic cancer patients after histolog-
ically confirmed by immunohistochemistry. The semi-
quantitative evaluation was conducted by Erkan M and
co-workers’ method [19]. Quantification was made by
the intensity of staining concluded by scores as follows:
① B7-H3positive cells / total cells in a microscope field
scored as: ≤33% of the cancer cells: 1, >33 to ≤66% of
the cancer cells: 2, >66% of the cancer cells: 3;② intensity
of staining-absent/weak: 1, moderate: 2, strong: 3. Each
section had a final grade that derived from the multiplica-
tion of the area and intensity scores. Sections with a final
score of ≤3 were classified as tumors with low B7-H3
expression (−), whereas sections with a final score of > 3
were classified as tumors with high B7- H3 expression (+).
MMP-2 expression was detected by Envision 2 step
method [20]. Mouse anti human MMP-2 mono clone
antibody and DAB developer were used in our study
(ZeHao Bio Co. LTD.) Briefly, removed the slides out at
−80°C, air dry at 60°C for about 30 min, and then dewaxed
by regular steps. Washed by 1 × PBS, 30 sec, wet autoclave
treatment for antigen 146 retrieval in Tris-EDTA, 3 min.
Apply 3% H2O2, incubated 10 min at RT. Primary
antibody was dilute to recommended concentration.
The slides were incubated over night at 4°C, washed
3 × 5 min in PBS1x. Secondary antibody: Apply 1 drop
Agent I, incubate 30 min at room temperature, washed
Table 2 B7-H3 mRNA expression results of 45 pancreatic
tumor tissue and 27 benign pancreatic tissues
B7-H3 mRNA expression P value
Normal 2.07 ± 0.60 0.000
Tumour 4.32 ± 2.05
Without lymph nodes metastasis 2.59 ± 1.12 0.000
Lymph nodes metastasis 5.70 ± 1.48
Survival <4 yr 4.89 ± 1.83 0.000
Survival >4 yr 2.04 ± 1.01
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bated for 10–15 min.
An image analyzer was used for quantification of im-
munoreactive of MMP-2, 10 selected fields of negative
controls were chosen to compare. The mean values of the
percentage of positive area for MMP-2 were recorded as
each tumor expression.
Survival analysis and statistical analysis
Kaplan-Meier survival curves were drawn to visually com-
pare the survival rates of 45 pancreatic cancer patients in
B7-H3 (+) MMP2 (+) group, B7-H3 (+) MMP2 (−) group,
B7-H3 (−) MMP2 (+) group and B7-H3 (−) MMP2 (−)
group at each TNM stage. The χ2 test, Fisher's exact
probability and t tests were performed in SPSS 17.0
software for data analysis. Differences were considered
statistically significant if P < 0.05.Table 3 The relationship between B7-H3 in pancreatic cancer
Pathologic parameter Cases(N) B7-H
Male 27 81.5 (
Female 18 72.2 (
Age < 60 19 73.7 (
Age ≥60 26 80.8 (
Located in head 37 81.1 (
Located in tail 6 66.7 (
Whole pancreas cancer 2 50 (1
Size of primary carcinoma(<3 cm) 30 86.7 (
Size of primary carcinoma(≥3 cm) 15 60 (9
Histodifferentiation(II) 26 96.2 (
Histodifferentiation(III) 7 57.2 (
Histodifferentiation(IV) 12 50 (6
Lymph nodes metastasis Negative 20 65 (1
Lymph nodes metastasis Positive 25 88 (2
pTNM stage I 9 22.2 (
pTNM stage II 11 72.7 (
pTNM stage III 12 100 (
pTNM stage IV 13 100 (
Normal tissue 27 0 (0/2
*P < 0.01.Results
Demographic data of patients
A total of 45 pancreatic cancer tissue samples obtained
successfully, 27 of them were males and 18 of them were
females, their age ranged in from 48 to 64 years (mean,
56.3 years), Table 1 showed the detailed clinical data of
these patients. The median follow-up period of these
pancreatic cancer patients were 29.6 months (8-64 month).
Another 27 cases of benign pancreatic tissues were chosen
as control.
Highly expressed B7-H3 mRNA in pancreatic tumor tissues
The B7-H3 mRNA expression is significantly higher in
45 pancreatic tumor tissues than 27 benign pancreatic tis-
sues (Table 2). In addition, the low 4- year survival rate of
pancreatic cancer patients is correlated with high B7-H3
expression level in pancreatic tumor tissue.
Low differentiated and metastatic patients have high B7-H3
protein expression
The positive expression rate of B7-H3 in pancreatic
cancer tissue is 77.8% (35 of 45) and is negative in all
benign tumor tissue. We summarized relationships be-
tween B7-H3 expression and clinicopathological results
in Table 3. Positive B7-H3 expression is associated with
low histo-differentiation, lymph node migration and TNM
stages. The poor prognosis is correlated with higher
positive B7-H3 in pancreatic cancer tissue but has notissue and associated clinical pathological factors
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tion, tumor size.
On the other hand, we observed negative B7-H3-
expression patients have higher survival rate compared
with positive patients (Figure 1), and the survival rate
decreased when tumor stage increased, histo-differentiation
decreased and lymph node migrated.Highly expressed MMP-2 in low differentiated and
metastatic patients
As we can see from Table 4, when compared with low
MMP-2 expression patients, the higher MMP-2 expres-
sion is, the worse prognosis of pancreatic cancer patients
is (P = 0.001). Positive MMP-2 expression is associated
with low histo-differentiation, lymph node migration
and TNM stages but is not associated with other clinicalFigure 1 The comparative graphs of survival rate of B7-H3.characters. Figure 2 showed the survival function on KM
estimator of MMP 2 in these pancreatic cancer patients.
B7-H3 expression is correlated with MMP-2 expression
Pearson correlation coefficients analysis for B7-H3 and
MMP-2 showed a significant correlations in pancreatic
patients (Pearson correlation = 0.496, P = .001), the increased
B7-H3 expression is correlated with higher MMP-2 in
pancreatic cancer samples (Table 5).
Discussion
In this section, we described the prognosis significant of
B7-H3 and MMP-2 expression alone and in combination
in pancreatic cancer patients who underwent surgical re-
section. B7-H3 expression has been extensively studied
in many kinds of malignant tumors for clinical diagnos-
tic and/or prognostic utilities [6,10,21]. In patients with
Table 4 The relation between the expression of MMP-2 and clinic-pathological factors
Pathologic parameter Cases(N) MMP2 expression positive rate % χ2 P value
Male 27 63.0 (17/27) 0.065 0.799
Female 18 66.7 (12/18)
Age < 60 19 73.7 (14/19) 1.225 0.268
Age ≥60 26 57.7 (15/26)
Located in head 37 67.6 (25/37) 0.886 0.642
Located in tail 6 50 (3/6)
Whole pancreas cancer 2 50 (1/2)
Size of primary carcinoma(<3 cm) 30 73.3 (22/30) 3.103 0.978
Size of primary carcinoma(≥3 cm) 15 46.7 (7/15)
Histodifferentiation(II) 26 84.6 (22/26) 11.109 0.004*
Histodifferentiation(III) 7 43.9 (3/7)
Histodifferentiation(IV) 12 33.3 (4/12)
Lymph nodes metastasis Negative 20 35 (7/20) 13.621 0.000*
Lymph nodes metastasis Positive 25 88 (22/25)
pTNM stage I 9 22.2 (2/9) 23.377 0.000*
pTNM stage II 11 45.5 (5/11)
pTNM stage III 12 75 (9/12)
pTNM stage IV 13 100 (13/13)
Normal tissue 27 0 (0/27)
*P < 0.01.
Xu et al. Cancer Cell International 2013, 13:81 Page 5 of 7
http://www.cancerci.com/content/13/1/81pancreatic cancer, the presence of B7-H3 expression has
been shown to correlate with poor prognosis, Zhao et al.
[22] detected that B7-H3 was significantly higher in pan-
creatic cancer tissue samples than that in normal pancreas
tissues. Evidence also showed that B7-H3 may serve as
an immunoinhibitory ligand which could promote tumor
progression. For instance, B7-H3 ligand was shown on
cell membranes of tumors obtained from children with
advanced stage IV, but not early stage I neuroblastoma
[23]. In a study of 70 patients with NSCLC, B7-H3 pro-
tein expressed was associated with an increased risk
for tumor metastases [24]. In present study, elevated
B7-H3 expression was detected in 77.8% of 45 pancreatic
cancer cases.
In consistent with protein expression, we tested a sig-
nificant increase of B7-H3 mRNA expression in pancre-
atic cancer tissue, like what was suggested by Arigami
[10], that blood specimens from patients with gastric
cancer contained significantly more copies of B7-H3
mRNA than those from healthy volunteers without
cancer (P < 0.0001).
TNM classification is commonly accepted clinicopath-
ologic predict prognosis for cancer patient. There have
been several attempts to correlate B7-H3 expression
with clinicopathologic variables, Takaaki et al. [10] found
that B7-H3 expression was higher in gastric tumor cellsthan normal cells, and the expression was significantly
correlated with overall stage. Some earlier studies also
reported similar results [24]. Our present studies found
that B7-H3 was more frequently elevated in pancreatic
cancer tissue with lymph node involvement and tumor
invasion. High B7-H3 expression was significantly asso-
ciated with low 4-years survival rate. Higher B7-H3 ex-
pression was correlated with higher TNM stages, which
indicates poor prognosis of the pancreatic cancer. But
B7-H3 could not be used to accurately discriminate in
age, gender, tumor location, size, stage. Therefore, B7-H3
expression analysis could be necessary,but not compre-
hensive for pancreatic cancer prognosis prediction.
Combination test of B7-H3 expression with other car-
cinogenesis prognostic factors has been used for achiev-
ing more sensitive and precise prognostic prediction.
Matrix metalloproteinases are a group of proteases that
play important roles in the processes of tumor invasion
and metastasis [13]. Recent studies have shown correlation
of MMP2 and B7-H3 expression on tumor migration and
immortality, Tekle et al. reported B7-H3 silencing of MDA-
MB-435 cells resulted in reduced metastatic capacity, and
significantly increased the median symptom-free sur-
vival of nude mice. Notably, the metastasis-associated
proteins, matrix metalloproteinase (MMP)-2, signal trans-
ducer and activator of transcription 3 (Stat3), and the level
Figure 2 The comparative graphs of survival rate of MMP2.
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B7-H3 knock-down cell variants [12]. However, there
has been no clear understanding of the prognosis sig-
nificant of B7-H3 and MMP-2 in pancreatic cancer
tissues. This is the first report to show a correlation
between the levels of B7-H3 and the levels of MMP-
2 in human pancreatic tumors, and these results sug-
gest that MMP and B7-H3 are good predictors for
pancreatic TNM stage.Table 5 Result of Pearson correlation coefficients analysis
for MMP-2 and B7-H3
B7-H3 MMP2
B7-H3 Pearson Correlation 1 .496*
Sig. (2-tailed) .001
N 45 45The current research also has some shortcomings, and
one of them is that the patient number in the subgroups
is not high enough to draw a very solid conclusion, so
further bigger population study is needed.
In conclusion, present study extends previous work;
we demonstrated that combined analyzing B7-H3 and
MMP-2 expression could predict prognosis of pancreatic
cancer. Combining test increases the diagnostic signifi-
cance over B7-H3 alone in pancreatic cancer patients.
The predictive value using these biomarkers reported in
this study is promising and warrants further validation
in other prospective longitudinal cohort studies, prefer-
ably in general populations to avoid the potential
patient selection bias inherent in most therapeutic/
prevention trials.Competing interest
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